DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

January 9, 2026

Study Completion Date

January 9, 2026

Conditions
AMISTEMINSTEMILeft Ventricular Dysfunction
Interventions
DRUG

Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)

"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."

DRUG

Placebo comparator

"Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."

Trial Locations (1)

75015

RECRUITING

Department of Cardiology AP-HP Hôpital européen Georges - Pompidou, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER